» Authors » Trevor J Pugh

Trevor J Pugh

Explore the profile of Trevor J Pugh including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 169
Citations 17098
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Sokolowski D, Miclaus M, Nater A, Faykoo-Martinez M, Hoekzema K, Zuzarte P, et al.
bioRxiv . 2024 Dec; PMID: 39651266
The naked mole-rat (NMR; ) is a eusocial subterranean rodent with a highly unusual set of physiological traits that has attracted great interest amongst the scientific community. However, the genetic...
2.
Kim S, Oldfield L, Kim R, Espin-Garcia O, Han K, Vicus D, et al.
J Surg Oncol . 2024 Nov; PMID: 39501493
Background And Objectives: Adoption of molecular classification in endometrial cancer (EC) into clinical practice remains challenging due to complexity in coordination of multiple assays. We aimed to develop a simple...
3.
Barbulescu P, Chana C, Wong M, Ben Makhlouf I, Bruce J, Feng Y, et al.
Nat Commun . 2024 Aug; 15(1):7541. PMID: 39215025
A diverse antibody repertoire is essential for humoral immunity. Antibody diversification requires the introduction of deoxyuridine (dU) mutations within immunoglobulin genes to initiate somatic hypermutation (SHM) and class switch recombination...
4.
Wong D, Tageldein M, Luo P, Ensminger E, Bruce J, Oldfield L, et al.
Nat Commun . 2024 Aug; 15(1):7386. PMID: 39191772
Germline pathogenic TP53 variants predispose individuals to a high lifetime risk of developing multiple cancers and are the hallmark feature of Li-Fraumeni syndrome (LFS). Our group has previously shown that...
5.
Hernando-Calvo A, Yang S, Vila-Casadesus M, Han M, Liu Z, Berman A, et al.
JCO Precis Oncol . 2024 Aug; 8:e2400100. PMID: 39178369
Purpose: Immune gene expression signatures are emerging as potential biomarkers for immunotherapy (IO). VIGex is a 12-gene expression classifier developed in both nCounter (Nanostring) and RNA sequencing (RNA-seq) assays and...
6.
Hernando-Calvo A, Han M, Ayodele O, Wang B, Bruce J, Abbas-Aghababazadeh F, et al.
Clin Colorectal Cancer . 2024 Jul; 23(3):272-284.e9. PMID: 38960798
Background: The use of immunotherapy in mismatch repair proficient colorectal cancer (pMMR-CRC) or pancreatic adenocarcinoma (PDAC) is associated with limited efficacy. DAPPER (NCT03851614) is a phase 2, basket study randomizing...
7.
Li J, Chin C, Ying H, Meydan C, Teater M, Xia M, et al.
Nat Commun . 2024 Apr; 15(1):2879. PMID: 38570506
Despite regulating overlapping gene enhancers and pathways, CREBBP and KMT2D mutations recurrently co-occur in germinal center (GC) B cell-derived lymphomas, suggesting potential oncogenic cooperation. Herein, we report that combined haploinsufficiency...
8.
Stutheit-Zhao E, Sanz-Garcia E, Liu Z, Wong D, Marsh K, Abdul Razak A, et al.
Cancer Discov . 2024 Feb; 14(6):1048-1063. PMID: 38393391
Significance: Analysis of methylation and fragment length in plasma using cfMeDIP-seq provides a tumor-naive approach to measure ctDNA with results comparable with a tumor-informed bespoke ctDNA. Early kinetics within the...
9.
Hernando-Calvo A, Nguyen P, Bedard P, Chan K, Saleh R, Weymann D, et al.
EClinicalMedicine . 2024 Feb; 69:102443. PMID: 38380071
Background: To date, economic analyses of tissue-based next generation sequencing genomic profiling (NGS) for advanced solid tumors have typically required models with assumptions, with little real-world evidence on overall survival...
10.
Lien S, Ly D, Yang S, Wang B, Clouthier D, St Paul M, et al.
Nat Commun . 2024 Feb; 15(1):1094. PMID: 38321065
Immunotherapies targeting PD-1/PD-L1 are now widely used in the clinic to treat a variety of malignancies. While most of the research on T cell exhaustion and PD-1 blockade has been...